Pay in 4 interest-free payments of $6.06 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Weight Loss and Metabolic Benefits: Obesity is a major risk factor for cardiovascular disease
In clinical trials, patients were sometimes allowed to stay at a lower dose for up to 8 weeks if needed to let side effects settle down
Next generation of obesity drugs - combination By the time Novo Nordisk's scientists had unlocked the potential of GLP-1 for obesity, a number of other researchers elsewhere were beginning to also explore its potential
Maybe two dozen
Three further Phase 3 trial results in the TRIUMPH programme are due before the end of 2026: TRIUMPH-2 in obesity with type 2 diabetes, TRIUMPH-3 in obesity with established cardiovascular disease (with further safety information relevant to higher-risk populations), and obstructive sleep apnoea
US$ 25.69
US$ 20.59
US$ 25.00
US$ 25.20
